Hey Market Enthusiast,

The story just leveled up. ⏫

Minutes before the opening bell, NanoViricides (NYSE Amer: NNVC) released new data showing that its lead drug NV-387 doesn’t just fight Measles infection — it protects the lungs from viral damage. (10)

That’s the kind of update that can move sentiment fast.

In fresh results from cell culture and humanized-animal studies, NV-387 showed direct antiviral activity and measurable protection of lung tissue, a critical factor in severe respiratory infections.

In treated models, survival increased by 130%, and histopathology revealed milder disease, fewer lung lesions, and sharply reduced immune-cell infiltration.

For context, there is still no approved drug anywhere for Measles. (10)

The company’s scientists described the finding plainly:

“NV-387 has dual benefits — directly reducing the virus itself, and protecting lungs from viral and immune-driven damage.”

That combination — viral control plus organ protection — is rare in antiviral development and could prove decisive as Measles cases surge nationwide.

The fresh data reinforces NV-387’s broad-spectrum design, built to mimic human cell receptors and destroy viruses before they can reinfect.

This morning’s release also reconfirmed the drug’s clean safety profile from Phase I: non-immunogenic, non-allergenic, non-mutagenic, and non-genotoxic.

With Measles clusters still expanding across the U.S. and globally, the timing could not be tighter.

Now let’s revisit what’s driving the setup in motion.

(1)

🧬 The Catalyst: NV-387 and the Measles Crisis (1)(8)(9)

The company’s latest announcement confirmed that its lead broad-spectrum antiviral, NV-387, has shown strong activity without toxicity against the Measles virus in a humanized animal model.

The company added that the medication can now be made available for emergency-use applications in Measles cases — exactly as the United States faces its worst outbreak in more than three decades.

🦠 The CDC has confirmed over 1,600 cases this year, breaking a 30-year record.

South Carolina just reported 15 active cases with more than 100 students quarantined, while new clusters in Ohio follow earlier flare-ups in Texas.

“We have already developed an effective dr.ug to respond to the Measles virus outbreaks spreading all across the country,” said company president Dr. Anil R. Diwan.

That statement changes the conversation.

With NV-387 already through Phase I human trials and no reported adverse events, NNVC can now support Physician-Initiated INDs — the regulatory pathway that lets doctors request emergency use for individual patients.

In short: the door is open for this compound to enter the real world.

⚙️ What Makes NV-387 Different (7)(8)(9)

NV-387 isn’t a vaccine or an antibody.

It’s a nanotech-based antiviral designed to trick viruses into binding to engineered polymers that mimic human cell receptors. Once the virus attaches, the polymer destroys it — attacking both extracellular and intracellular infection pathways.

That dual action could make NV-387 effective across a wide range of pathogens. The company says its design targets binding sites shared by about 90% of human viruses, giving it genuine broad-spectrum potential.

In animal studies, NV-387 has shown strong results against RSV, Influenza, COVID-19, and Smallpox/Mpox.

In a Measles model, it increased survival by 130% compared to untreated controls with no observed toxicity. By contrast, Ribavirin — the only unapproved fallback sometimes used off-label for Measles — is known to be highly toxic.

NV-387 is already manufactured under GMP standards in the U.S., and the company notes it can be produced as oral gummies that dissolve slowly in the mouth — a useful detail for symptomatic patients.

🧩 Broader Pipeline Context (1)(4)(7)

NanoViricides is positioning NV-387 as a platform medication, not a single-virus solution. The same molecule is being advanced for multiple respiratory and epidemic threats including Bird Flu (H5N1), RSV, Influenza, COVID-19, and Mpox/Smallpox.

Earlier this year, regulators in the Democratic Republic of Congo cleared NNVC to file a Phase II clinical-trial application for NV-387 in Mpox disease, a virus with a fatality rate several times higher than COVID’s.

A second candidate, NV-HHV-1, is in preparation for Phase I studies targeting all Herpes-family viruses, including HSV-1 cold sores, HSV-2 genital ulcers, and shingles.

Each of these programs draws from the same nanoviricide framework — one chemistry, many targets — a model that could eventually scale into multiple therapeutic categories.
 

(1)

🌡️ Why This Matters Right Now (4)(7)(8)(9)

The U.S. is on the verge of losing its Measles elimination status for the first time since 2000.

Vaccine coverage has slipped, immunity gaps are widening, and the virus itself has drifted genetically from its original vaccine strain.

That creates an urgent need for a treatment, not just prevention.

NV-387 now sits at the center of that conversation.

If emergency use proceeds — even in limited cases — it would mark the first real-world deployment of NanoViricides’ platform and a major validation moment for the company’s underlying technology.

Add to that the upcoming Mpox Phase II clearance, and NNVC suddenly has two high-visibility catalysts pointing in the same direction:

 real human data, real regulatory traction, real urgency.

💡 Market Perspective (2)(6)

Biotech headlines move fast, but few names have this combination of conditions:

a technical breakout setup, a multi-virus pipeline, and a public-health storyline that’s front-page relevant.

As of the last filing period, NNVC reported roughly $1.6 million in cash, which means financing risk is real — but that also means every milestone announcement carries leverage.

If the company’s science continues to hold up, small moves in perception could translate into large percentage shifts on the chart.

Volatility is high, expectations are rising, and the window for confirmation is narrowing.

🧭 The Takeaway (1)(4)(9)

From RSV to Mpox to Measles, NanoViricides is building a narrative around a single molecule designed to challenge how viral diseases are treated.

The science is ambitious. The setup is live.

With outbreaks spreading and emergency-use language now in play, NNVC’s next phase may unfold in the public eye.

📊 Keep this one on screen. When a broad-spectrum story aligns with real-world headlines, momentum can move quickly.

To your success,

Max Masters

Co-founder, Market Tips Newsletter

Sources:
1. https://www.nanoviricides.com/
2. https://finance.yahoo.com/quote/NNVC/
3. https://www.biospace.com/nanoviricides-reports-that-the-phase-i-nv-387-clinical-trial-is-completed-successfully-and-data-lock-is-expected-soon
4. https://www.biospace.com/press-releases/broad-spectrum-antiviral-drug-nv-387-cleared-for-phase-ii-clinical-trial-application-by-the-national-ethics-committee-of-the-democratic-republic-of-congo
5. https://www.biospace.com/press-releases/measles-outbreak-expands-begging-for-a-drug-to-treat-the-infection-nanoviricides-declares-it-is-ready-to-fight-the-outbreak
6.https://www.sec.gov/Archives/edgar/data/1379006/000141057825001336/nnvc-20250331x10q.htm 
7. https://www.proactiveinvestors.co.uk/companies/news/1070900/nanoviricides-wins-ethics-approval-for-phase-ii-mpox-drug-trial-in-drc-1070900.html
8. https://www.nbcnews.com/health/health-news/measles-outbreak-frustration-quarantines-ohio-south-carolina-rcna237947
9. https://finance.yahoo.com/news/measles-drug-strong-activity-without-124500247.html
10. https://finance.yahoo.com/news/treating-measles-infection-nv-387-124500555.html

Paid Promotion. Momentum Media LLC has been hired for a period beginning on 10/21/2025 and ending on 10/22/2025 (the “Campaign”) to publicly disseminate information about NanoViricides, Inc. (NNVC:US). Momentum Media LLC has been compensated $7,500 and are owed an additional $0 for the Campaign. To date we have been paid $25,000. Please read Momentum Media LLC’s complete disclaimer at https://markettips.net/disclaimer/ which includes important information. Emojis, graphics and/or images used herein have no specific or implied meaning, and are used for artistic purposes only. Nothing contained herein is financial advice. Momentum Media LLC is not an analyst, st.o.ck broker, financial adviser or st.o.ck picker nor is it qualified to act in the capacity of any of the foregoing. Information herein is a paid advertisement and should not be relied upon as accurate or complete.